High-Dose Semaglutide (Up to 16 mg): Exploring Higher Doses for Greater Benefit
Study of high-dose semaglutide up to 16 mg in T2D patients explores whether doses beyond current approvals provide additional metabolic and weight benefits.
Quick Facts
What This Study Found
Study of high-dose semaglutide up to 16 mg in T2D patients explores whether doses beyond current approvals provide additional metabolic and weight benefits.
Key Numbers
245 participants randomized. Semaglutide doses: 2 mg, 8 mg, 16 mg weekly (subcutaneous). All on metformin with BMI ≥27.
How They Did This
In publication.
Why This Research Matters
Relevant to peptide therapeutics.
The Bigger Picture
Advances peptide evidence.
What This Study Doesn't Tell Us
In publication.
Questions This Raises
- ?Long-term implications?
- ?Evidence comparison?
- ?Next steps?
Trust & Context
- Key Stat:
- Key finding Study of high-dose semaglutide up to 16 mg in T2D patients explores whether doses beyond current app
- Evidence Grade:
- Based on design.
- Study Age:
- Published in 2025.
- Original Title:
- High-Dose Semaglutide (Up to 16 mg) in People With Type 2 Diabetes and Overweight or Obesity: A Randomized, Placebo-Controlled, Phase 2 Trial.
- Published In:
- Diabetes care, 48(6), 905-913 (2025)
- Authors:
- Aroda, Vanita R(4), Jørgensen, Nils B(2), Kumar, Bharath(2), Lingvay, Ildiko, Laulund, Anne Sofie, Buse, John B
- Database ID:
- RPEP-09981
Evidence Hierarchy
Frequently Asked Questions
What does this mean?
Study of high-dose semaglutide up to 16 mg in T2D patients explores whether doses beyond current approvals provide additional metabolic and weight benefits.
How reliable?
Consult publication.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09981APA
Aroda, Vanita R; Jørgensen, Nils B; Kumar, Bharath; Lingvay, Ildiko; Laulund, Anne Sofie; Buse, John B. (2025). High-Dose Semaglutide (Up to 16 mg) in People With Type 2 Diabetes and Overweight or Obesity: A Randomized, Placebo-Controlled, Phase 2 Trial.. Diabetes care, 48(6), 905-913. https://doi.org/10.2337/dc24-2425
MLA
Aroda, Vanita R, et al. "High-Dose Semaglutide (Up to 16 mg) in People With Type 2 Diabetes and Overweight or Obesity: A Randomized, Placebo-Controlled, Phase 2 Trial.." Diabetes care, 2025. https://doi.org/10.2337/dc24-2425
RethinkPeptides
RethinkPeptides Research Database. "High-Dose Semaglutide (Up to 16 mg) in People With Type 2 Di..." RPEP-09981. Retrieved from https://rethinkpeptides.com/research/aroda-2025-highdose-semaglutide-up-to
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.